Fig. 5
From: Administration of anti-ERMAP antibody ameliorates Alzheimer’s disease in mice
Anti-ERMAP mAb increases the proportion of T cells and the CP activity. 3XTg-AD mice were injected with anti-ERMAP, or control mAb as in Fig. 3. Three and a half months later, the spleen and CP were harvested. The splenocytes were analyzed for the percentages of A–D CD4 and CD8 T cells, and E, F IFN-γ-producing CD4 T cells by flow cytometry. The CP was analyzed for G, H the percentage of IFN-γ-producing CD4 T cells by flow cytometry, and I the mRNA expression levels of IFNγ, ccl3, cxcl12, icam1, and vcam1 by qRT-PCR. The expression levels of the genes in control mAb-treated AD mice are defined as 1. The data are expressed as mean ± SD from one of three independent experiments with similar results (5–8 mice per group in each experiment). *P < 0.05 versus control mAb group